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showed a strong trend for less CV-events (p = 0.098). Cost-
effectiveness of screening for elevated albuminuria was.
€16,559/LYG (from €7,030 to €24,125 in sensitivity analysis).
Stochastic analysis indicated that the probability of cost-
effectiveness below the suggested Dutch threshold for cost-
effectiveness of €20,000 per LYG is 60% in the baseline 
analysis, increasing to 91% if only those subjects are treated with
fosinopril showing a UAE >50mg/24hr. Also, limiting screening
to only those aged greater or equal than 50; improved cost-
effectiveness considerably. CONCLUSION: Primary prevention
by screening the general population for the risk marker albu-
minuria greater or equal to 15mg/24hr and subsequent treat-
ment with fosinopril of those found positive to reduce the
incidence of CV events may well be cost effective.
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OBJECTIVES: To evaluate short-term (12 months) cost-
effectiveness (CE) of intravenous (iv) vitamin D preparations
(paricalcitol and calcitriol) to control hyperparathyroidism in
hemodialysis patients. METHODS: A decision analytic model
was constructed and analysed from the hospital and the Italian
National Health System (INHS) perspectives. Following the indi-
cations of the Italian Nephrology Society on the use of iv Vitamin
D analogues, patients were simulated to start a 12-month iv
Vitamin D treatment when parathormone (PTH) plasmatic level
was >700pg/ml. Starting doses were 27mg/week for paricalcitol
and 9mg/week for calcitriol; subsequent maintenance dose was
adjusted assuming decreasing PTH levels over time. Model para-
meters were derived from multiple published sources. Clinical
course of treatment and efﬁcacy in controlling hyperparathy-
roidism were based on a RCT (Sprague SM. Kidney Int 2003);
effect on survival, hospitalisation rate and length-of-stay (LOS)
were based on retrospective studies (Teng M. NEJM 2003;
Dobrez DG. Nephrol Dial Transplant 2004). Cost included drug
costs (hospital prices excluding taxes), cost per hospitalization
(national mean DRG value, 2002), in the INHS perspective, or
cost per day of hospitalization (general medical ward, Lucioni
C. et al. Treat Endocrinol 2003), in the hospital perspective.
RESULTS: Per patient one-year drug acquisition costs were
€3364.74 for paricalcitol and 1883.25 for calcitriol. Calcitriol
patients had an average of 0,846 hospitalizations/year more than
paricalcitol at an incremental cost, in the INHS perspective
(DRG tariffs), of €2868.69. Calcitriol patients had an average 
of 9.17 hospitalization/days more than paricalcitol at an incre-
mental cost, in the hospital perspective (LOS), of €2249.58. Par-
icalcitol strategy resulted dominant in both perspectives.
Robustness of these ﬁndings was demonstrated in multiple sen-
sitivity analyses. CONCLUSIONS: In Italy, paricalcitol greater
acquisition costs are offset by reduction in hospitalizations 
and LOS both from an NHS perspective and from the hospital
perspective.
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OBJECTIVES: To demonstrate cost-effectiveness (ICER) of
Mimpara (MIM), a drug against secondary hyperparathyroidism
(sHPT) in dialysis, compared to standard treatment of care
(SOC). METHODS: A Markov model operates in 1/2 year cycles
and runs over 16 years until the starting cohort reaches 70 years.
Mortality risk per cycle was calculated from a 2-year cohort dial-
ysis database (n = 13,000)1. The model uses speciﬁc distributions
for parathyroid hormone (PTH), Calcium (Ca) x Phosphor (P),
age, vintage and MIM dosages (30–120mg/day) from phase III
trials. Patients withdrawing from MIM were treated with SOC.
Average drug costs were €3109/year ﬁrst cycle and €2617/year
subsequent cycles as only drug responders (85%) remained on
study drug. Other treatment costs were taken from a retrospec-
tive cost study in Belgium2 using average daily cost of €214 per
dialysis patient plus €50/day for sHPT-sufferer. Annual 3% dis-
count rate was applied to cost and outcome data. RESULTS:
Running the model in Monte-Carlo simulation (10,000 itera-
tions) over 16 years, delivered a mortality difference of 0.17
years favoring MIM-use for an extra cost of €8027 (+ dialysis
cost) resulting in an ICER of €47,218 per Life Year Gained.
Excluding dialysis costs the ICER was €36,970. Sensitivity analy-
ses ranging discount rates from 0% to 6% independently for
both outcome and cost data showed ICERs of €36,970 and
€59,459 for outcome and €64,517 and €35,088 for cost results,
respectively. Evaluating the ICERs over time indicates that cost-
savings may appear early in MIM-treatment (ﬁrst 2 to 3 years)
due to reductions in co-morbidities without observable survival
beneﬁt. CONCLUSION: Including dialysis costs in the ICER-
equation maintained a reasonable CE-result (<€50,000/LYG)
favoring the use of Mimpara for sHPT.
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OBJECTIVES: Kidney transplantation (KT) is generally
acknowledged as the most clinically effective and cost-effective
option in managing ESRD patients. The objective of our study
was to identify costs and estimate cost-effectiveness of various
ESRD treatment modalities in Latvia. METHODS: We retro-
spectively analysed ﬁles of 250 patients in an in-center hemodial-
ysis treatment mode (HD), 60 patients in continuous ambulatory
peritoneal dialysis treatment mode (CAPD) and 51 patients after
successful KT for the ﬁrst 3 years of treatment. All direct medical
costs were registered. Cost-effectiveness was estimated by costs
per 3 life-years gained. RESULTS: Mean direct costs (in 2003 €)
for one patient for the ﬁrst year and all three years of treatment
were: for CAPD 16,250.0 + €1,577.4 and 48,327.7 ± 1, €162.2
respectively, for HD 14,131.7 ± €1,212.4 and 42,052.4 ±
€1,203.2 respectively, and for KT 15,880.0 ± €4,744.7 and
25,460.0 ± €2,994.4 respectively. Average treatment costs per
patient over the 3 years were the highest in the CAPD group (P
< 0.05 vs. HD, P < 0.001 vs. KT) and KT was the least expen-
sive (as expected). The initial higher costs of KT were fully
recouped within 15 months after surgery. Probability of life
expectancy for CAPD, HD and KT for the ﬁrst and third year
were: 77.3%, 84.1% and 91.3% respectively, and 45.0%, 43.l%
and 83.7% (P < 0.001 vs. CAPD and HD), respectively. The cost
of 3 life-years gained by KT was signiﬁcantly less (P < 0.001)
than the cost associated with CAPD and HD (€29,598.5 vs.
€106,661.1 and €97,798.5 respectively). CONCLUSIONS:
Compared to CAPD and HD, KT provided greater survival ben-
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eﬁts to patients with ESRD, at a lesser cost. It may be more cost-
effective to manage patients starting on RRT with preemptive
KT or HD, than CAPD.
PUK12
ASSESSING THE EFFICIENCY OF INTERSTIM® IN FECAL
INCONTINENCE (FI) IN THE SPANISH SETTING.A COST-
EFFECTIVENESS SIMULATION MODEL
Brosa M1, Navarro A2, Rodriguez JM3, Serrano-Contreras D4
1Oblikue Consulting, Barcelona, Spain; 2Hospital Mutua de Terrassa,
Terrassa, Barcelona, Spain; 3Medtronic Iberica, Madrid, Spain;
4Medtronic Iberica, Madrid, Madrid, Spain
Fecal incontinence (FI) is one of the most psychologically and
socially debilitating condition in an otherwise healthy individ-
ual. Sacral Nerve Stimulation (SNS) is the option in cases where
conservative treatments have been ineffective and before under-
going surgery procedures like dynamic graciloplasty or artiﬁcial
anal sphincter in patients with intact anal sphincter (IAS) and
before Sphincteroplasty in patients with structural deﬁcient anal
sphincter (SDAS). Interstim® is a relatively new effective and
safety therapy that has shown to be more effective than surgery
in almost all patients. OBJECTIVE: To asses the efﬁciency of
introducing Interstim® in management of patients suffering FI in
the Spanish setting using a cost-effectiveness model. METHODS:
A decision analytic model was developed to estimate the costs
and outcomes of patients with FI managed with and without
Interstim®. Clinical and economic data were retrieved from pub-
lished studies and an expert panel. The analysis was run over a
5 years time horizon from a NHS perspective and the primary
outcome was quality-adjusted life years (QALYs). Cost data were
obtained from SOIKOSTM Spanish’s health care costs database.
Costs and beneﬁts were actualized to euros 2004 and discounted
at 3% annum. Sensitivity analyses were performed in order to
handle uncertainty. RESULTS: Preliminary results show that the
introduction of Interstim® in the management of FI increases
treatment costs in 1211 in IAS patients and 1024 in SDAS
patients (5246 to 6456 and 7648 to 8671 respectively), yielding
to improvement in quality adjusted life expectancy of 0.234 and
0.228 respectively. Discounted cost per QALY gained of the
introduction of Interstim® are 5182 and 4486. CONCLUSIONS:
The use of Interstim® as an alternative to current surgical pro-
cedures in certain circumstances (as second or third treatment
line in IAS and SDAS IF patients) is associated to an improve-
ment of IF patients at a reasonable extra cost.
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OBJECTIVES: To compare both drugs in terms of efﬁcacy and
costs. METHODS: The efﬁciency of incontinence treatment, as
perceived by third party payer, will be calculated. Due to com-
parable efﬁcacy, a cost-minimisation-analysis was conducted to
evaluate the costs of a treatment of urinary incontinence with
trospium chloride and with oxybutynin. Based on data obtained
from literature, a decision tree model was compiled to portray
the course of treatment. Adverse drug reactions (ADR) were also
be considered. Costs for treatment of incontinence, treatment of
ADR, and for second-line therapy taken if the treatment failed,
will be taken into consideration. After calculation of all the
emerged costs, total costs were determined by means of the
DATA-program. To analyse the inﬂuence of different parameters
on total costs, from the perspective of the statutory health insur-
ance, two sensitivity-analyses were conducted. RESULTS: Tro-
spium chloride caused third party payer expenses amounting to
€2,032, whereby the expenses for oxybutynin were €1968.
Because of the higher drug costs of trospium chloride, the treat-
ment costs were accordingly 3.3 % higher. The model was
proven robust. CONCLUSION: Treatment of urinary inconti-
nence with trospium chloride is as efﬁcacious as the well-estab-
lished oxybutynin and costs are comparable despite the higher
price of trospium chloride. The advantages however of trospium
chloride over oxbutynin are obvious by its adverse event
proﬁle—the risk of ADR is reduced. From the above mentioned
facts, it may be concluded that the treatment of urinary inconti-
nence with trospium chloride offers an adequate treatment alter-
native from the perspective of the statutory health insurance in
Germany.
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OBJECTIVES: Since 1992, legislative actions were taken to face
the increasing pharmaceutical expenditure in Italy. In this
context, evaluating the cost of illness on the NHS and the patient
becomes crucial, especially for high prevalence conditions, like
females LUTS. METHODS: This economic evaluation is part of
the FLOW project, a 2-year observational study aimed at eval-
uating the frequency and clinical progression of symptoms in
Italian women suffering from LUTS for >=3 months presenting
at 39 Urology Centres. Data on NHS expenditure such as spe-
cialist visits, hospitalization, therapy and laboratory tests were
collected retrospectively between May 2002 and May 2003.
Direct costs sustained by patients were collected using the
Dowell-Bryant Incontinence Cost Index (DBICI) which investi-
gates costs of disposable pads, re-usable incontinence products,
laundry expenditure, health professional expenditure,
surgery/diagnostic investigation and medication. RESULTS:
Costs sustained by NHS: After a one-year follow-up, 550 women
[mean (SD) age = 53.5 (13.8) years] were evaluated. The direct
yearly total cost for this cohort was €284.943,08. Of the total
expense, more than half (50.8%) was devoted to surgical
therapy, 30% to laboratory and instrumental tests and 12.5%
to rehabilitative therapies. The estimated annual average direct
cost per patient with LUTS was €518,08. For the urinary incon-
tinence (UI) group the annual expense was €635,00. Costs sus-
tained by patients: 200 women with UI compiled the DBICI.
Estimated annual average expenditure per patient was 276.04
euro. Of the total personal expenditure, the disposable inconti-
nence products accounted for 38% and medication for 22%.
CONCLUSION: In Italy, little is known about the economic
impact of LUTS. UI seems to be the most expensive LUTS
problem from the NHS point of view. Diapers and medication
represent the most expensive products for the patient.
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